Skip to content

Diagnostic value and clinical research of single-cell immune function characterization in time-series analysis of tuberculosis infection

Diagnostic value and clinical research of single-cell immune function characterization in time-series analysis of tuberculosis infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099506
Enrollment
Unknown
Registered
2025-03-25
Start date
2023-07-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Tuberculosis patient Group:None
Mycobacterium tuberculosis latent infection group:None

Sponsors

Suzhou Fifth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The population included in this study can be divided into the following three categories: 1. Pulmonary tuberculosis patients: according to WS299-2017 "Diagnosis of Tuberculosis", 1) aged 18-65 years old; 2) patients with definite diagnosis of pulmonary tuberculosis or clinical diagnosis of pulmonary tuberculosis in our hospital; 2. Latent infection of Mycobacterium tuberculosis: according to WS196-2017 classification of tuberculosis, 1)aged 18-65 years old; 2) Ifn-? release test was positive; 3) no imaging signs of active or old tuberculosis; 4) no clinical symptoms of active tuberculosis such as fever, cough, night sweats and weight loss; 5) no previous history of tuberculosis. 3. Healthy people: 1) age >=18 years old; 2) Interferon-? release assay was negative; 3) no imaging signs of active or old tuberculosis; 4) no clinical symptoms of active tuberculosis such as fever, cough, night sweats and weight loss; 5) no previous history of tuberculosis; 6)denying the history of tuberculosis exposure.

Exclusion criteria

Exclusion criteria: Patients who met any of the following criteria were excluded: 1.pregnant or lactating patients; 2. patients with hematological malignancies; 3. people living with HIV; 4.suffering from autoimmune diseases; 5. immunosuppressive therapy; 6. after organ transplantation or hematopoietic stem cell transplantation.

Design outcomes

Primary

MeasureTime frame
Single-cell multiplexed secretome proteomics;

Secondary

MeasureTime frame
Expression of serum cytokines;

Countries

China

Contacts

Public ContactPing Xu

Suzhou Fifth People's Hospital

573311485@qq.com+86 130 1380 7540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026